{"schema_version":"secwatch.filing_event.v1","accession":"0001048477-25-000004","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2025-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.798176+00:00","generated_at":"2026-05-26T10:17:58.970334+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BioMarin reports Q4 revenue $747M (+16%), full-year GAAP EPS $2.21, guides 2025 rev growth ~10%","bullets":["Q4 total revenue $747M (+16% YoY); full-year $2.854B (+18%). GAAP diluted EPS $0.64 (Q4) and $2.21 (FY), up 154% YoY.","Non-GAAP diluted EPS $0.92 (Q4) and $3.52 (FY), up 69% YoY. Non-GAAP operating margin 28.6% for FY, up 9.2 ppts.","VOXZOGO revenue $208M in Q4 (+42%), $735M full-year (+56%); on track for >25% CAGR 2023-2027.","FY 2025 guidance: total revenue growth ~10% at midpoint; non-GAAP diluted EPS growth ~22%; targeting $4B revenue by 2027.","Pipeline: BMN 333 (CNP) first-in-human dosed, BMN 351 DMD data H2 2025; PALYNZIQ adolescent study data mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001048477-25-000004","json":"https://secwatch.observer/filing/0001048477-25-000004.json","markdown":"https://secwatch.observer/filing/0001048477-25-000004.md","text":"https://secwatch.observer/filing/0001048477-25-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000104847725000004/0001048477-25-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000104847725000004/bmrn-20250219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T10:17:58.970334+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}